RYR2 and catecholaminergic polymorphic ventricular tachycardia: This indirect, RyR2-mediated effect may be the basis for the recent use of flecainide monotherapy in human CPVT, although here individuals are usually heterozygotic and thus flecainide could be acting on both WT and mutant RyR2 [34,35,36].